4 Comments

A couple of weeks ago, didn't Johnson and Johnson release data indicating that their vaccine shows no waning at all after six months? (That was the one-dose original regimen. Presumably the two-dose version would last even longer.)

Expand full comment

Since we don’t have data on the waning of the same endpoint for Pfizer, it’s pretty hard to make any comparison here, but the J&J effectiveness was always lower to begin with after a second dose. Since we’re comparing very different populations, vaccines, and endpoints here it’s very hard to say whether there’s a meaningful difference between vaccines in this regard. Maybe it’s just that every vaccine settles out at the ~68% effectiveness against disease that a single dose of J&J started with. That wouldn’t be so bad, really.

Expand full comment

Until very recently J&J didn't have a second dose. It's the experimental second dose that's raising efficacy to a claimed 94% (in the United States) against symptomatic disease.

https://www.statnews.com/2021/09/21/johnson-johnson-says-additional-dose-boosts-covid-vaccine-efficacy/

Expand full comment

Sorry, that was a brain fart. I meant to say “after a single dose.” Probably the comment makes more sense now.

Expand full comment